SCHEMBL1122453

SCHEMBL1122453

Nc1ccc2c(c1)OOCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.40
KDM4E B2RXH2 5/20 0.40
GAA P10253 5/20 0.40
SMN1; SMN2 Q16637 4/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 3/20 0.34
CA9 Q16790 2/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
MITF O75030 1/20 0.34
MAPK1 P28482 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
LMNA P02545 3/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
HPGD P15428 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3838626 0.89 MAPT (0.38) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL30273127 0.84 MAPT (0.40) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL1122456 0.84 MAPT (0.40) MAPTKDM4EGAASMN1; SMN2MEN1
Hydrochloric Acid SCHEMBL4269942 0.82 MAPT (0.43) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL655314 0.79 MAPT (0.52) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL2098339 0.79 CA9 (0.40) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL6725684 0.76 LMNA (0.41) MAPTTDP1LMNA
SCHEMBL8577915 0.76 ALDH1A1 (0.34) MAPTGAAALDH1A1HSD17B10
SCHEMBL29739347 0.72 MAPT (0.48) MAPTKDM4EGAASMN1; SMN2MEN1
SCHEMBL7004647 0.72 MAPT (0.48) MAPTKDM4EGAASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12616193-B2 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility SPERMATECH AS (NO) 2026-05-05 US disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 US disclosed
EP-4142716-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY Spermatech AS (NO) 2023-03-08 EP disclosed
CN-115768260-A 5- (1H-indol-3-yl) -oxazole, -oxadiazole and-furan derivatives as sperm motility enhancers 精液技术股份有限公司 2023-03-07 CN disclosed
WO-2021220012-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2021-11-04 WO disclosed
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2020-02-27 US disclosed
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2019-03-05 US disclosed
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION ABIONYX PHARMA (FR) 2018-03-08 US disclosed
EP-3241833-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION Cerenis Therapeutics Holding SA (FR) 2017-11-08 EP disclosed
US-9757381-B2 Compounds, compositions and methods useful for cholesterol mobilization CERENIS THERAPEUTICS HOLDING SA (FR) 2017-09-12 US disclosed
US-20130267554-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CERENIS THERAPEUTICS HOLDING SA (FR) 2013-10-10 US disclosed
EP-2629776-A2 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION Cerenis Therapeutics Holding SA (FR) 2013-08-28 EP disclosed
US-8349833-B2 Compounds, compositions and methods useful for cholesterol mobilisation CERENIS THERAPEUTICS HOLDING SA (FR) 2013-01-08 US disclosed
US-20120129856-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CERENIS THERAPEUTICS SA (FR) 2012-05-24 US disclosed
WO-2012054535-A2 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CERENIS THERAPEUTICS SA (FR) 2012-04-26 WO disclosed
EP-1831184-B1 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS WELLCOME TRUST LTD (GB) 2011-02-09 EP disclosed
US-7737152-B2 6-carboaryl-oxy-pyrazin-2-yl-carboaryl-amines and compositions comprising said compounds THE WELLCOME TRUST LIMITED (GB) 2010-06-15 US disclosed
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds THE WELLCOME TRUST LIMITED (UK) 2008-01-17 US disclosed
EP-1831184-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS The Wellcome Trust Limited (GB) 2007-09-12 EP disclosed
WO-2006067466-A2 PYRAZINES AND PYRIDINES AND DERIVATIVES THEREOF AS THERAPEUTIC COMPOUNDS THE WELLCOME TRUST LIMITED (GB) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064718-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 MAPT 2213/4885KDM4E 4338/4885GAA 284/4885
US-10220040-B2 Compounds, compositions and methods useful for cholesterol mobilization CETP, LIPA, NPC1L1 MAPT 2213/4885KDM4E 4338/4885GAA 284/4885
US-20120129856-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION CETP, NPC1L1, NPC1 MAPT 1542/4885KDM4E 4403/4885GAA 300/4885
US-12616193-B2 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility NR5A1, CATSPER1, HCN3 MAPT 4866/4885KDM4E 3674/4885GAA 4816/4885
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 MAPT 4855/4885KDM4E 3913/4885GAA 4846/4885
US-20130267554-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 MAPT 2213/4885KDM4E 4338/4885GAA 284/4885
US-20080015191-A1 Pyrazines and Pyridines and Derivatives Thereof as Therapeutic Compounds BRAF, RAF1, BCOR MAPT 4774/4885KDM4E 2382/4885GAA 4871/4885
US-20200061072-A1 COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION CETP, LIPA, NPC1L1 MAPT 2213/4885KDM4E 4338/4885GAA 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.